Uncategorized
Types of Ketamine Therapy: How Dosages Are Determined
Jul
Ketamine therapy encompasses multiple administration routes, dosing protocols, and care frameworks — each with distinct clinical trade-offs that shape your treatment experience and outcomes. This article explains how providers determine dosing, what differentiates each route of administration, and why the care framework surrounding the medication matters as much as the dose itself.
What Are the Different Types of Ketamine Therapy?
Ketamine therapy is categorized primarily by how the medication is administered. Each route has distinct bioavailability, onset time, duration, setting requirements, and cost implications. Below is a breakdown of the six most common administration routes used in clinical practice.
Intravenous Ketamine Therapy
IV ketamine delivers the medication directly into the bloodstream through a vein. You typically receive IV infusions in a dedicated facility such as a ketamine clinic or hospital.
Intravenous delivery offers the highest bioavailability of any method, reaching close to 100%. Effects begin quickly, typically within minutes of starting the infusion. Sessions typically last 40 to 60 minutes of infusion time. The process requires in-facility administration with clinical staff present and vital-sign monitoring. Dosing is weight-based and titrated by the administering provider in real time. IV is often considered the most-studied route for depression.
IV ketamine requires dedicated facility visits and is typically the most expensive option per session. It is offered exclusively in supervised settings. IV suits individuals who prioritize the most precise dose control and real-time clinical monitoring.
Intramuscular Ketamine Therapy
IM ketamine is injected into a large muscle, typically the deltoid or gluteal muscle. The medication is then absorbed into the bloodstream from the tissue.
Approximately 93% of the administered dose reaches systemic circulation. Onset is slightly slower than IV, taking 5 to 15 minutes to begin. Intramuscular delivery does not require IV access or infusion equipment, which simplifies administration. A healthcare provider typically administers the injection in a supervised setting. Dosing is weight-based, and the session duration is comparable to IV.
IM ketamine offers a simpler setup than IV while maintaining high bioavailability. Some facilities use it as an alternative to IV infusion for clients who want a simpler delivery method. You still receive the in-person monitoring environment.
Intranasal Ketamine Therapy
Intranasal ketamine is sprayed into the nasal passages. The most well-known form is Spravato (esketamine), the only FDA-approved ketamine-derived medication, indicated with an oral antidepressant for adults with treatment-resistant depression and, separately, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Generic racemic ketamine can also be compounded as a nasal spray for off-label use.
Spravato uses esketamine, the S-enantiomer of ketamine, rather than racemic ketamine. You must receive it in a certified healthcare setting under the Spravato REMS program. The program requires a mandatory two-hour observation period after each dose. Between 25 and 50% of the intranasal dose reaches systemic circulation. Compounded nasal sprays follow a different regulatory pathway than Spravato and are dispensed under standard prescribing rules rather than REMS oversight.3
Spravato’s FDA approval reflects its specific regulatory pathway for treatment-resistant depression and major depressive disorder with suicidal ideation. FDA approval does not by itself indicate superiority over other ketamine routes. The choice of route depends on individual clinical factors and goals. Its delivery model requires in-office visits and post-dose monitoring, which shapes cost and accessibility. Compounded nasal sprays are an off-label intranasal ketamine option with a different regulatory pathway than Spravato, and they do not use Spravato’s standardized dosing or REMS oversight.
Therapeutic-Dose Sublingual Ketamine Therapy
Therapeutic-dose sublingual ketamine involves placing a tablet, troche, or rapid-dissolve formulation between the cheeks and gums. You hold the medication for a specified period, typically 7 to 15 minutes, to allow absorption through the oral mucosa. Some protocols direct that the remaining medication is then spit out to avoid gastrointestinal upset, while others do not.
Sublingual bioavailability is reported in a range of approximately 25 to 35%, varying with the protocol used. Posted milligram amounts are higher than IV or IM doses for equivalent therapeutic effect because of this lower absorption rate. The prescribing specialist titrates the dose across sessions based on individual response. Sublingual administration produces a transient dissociative experience at therapeutic doses. Most people find the dissociative state therapeutically meaningful within a supervised setting.
Key attributes of therapeutic-dose sublingual ketamine include:
- Onset: Effects typically begin within 10 to 15 minutes.
- Session duration: Most sessions last 45 to 60 minutes.
- Protocol: Hold-and-spit, or hold-and-swallow depending on the provider.
- Setting: Conducted at home with a required peer treatment monitor present.
- Oversight: Supervised by a licensed provider via telehealth protocols.
Sublingual delivery is the most common route for at-home ketamine therapy. It has the largest body of published real-world outcomes data in the at-home context. Mindbloom’s peer-reviewed research studied this specific format.4,9
Low-Dose, Daily Sublingual Ketamine Therapy
Some telehealth providers prescribe sublingual ketamine at sub-perceptual doses taken daily or near-daily. These protocols use significantly lower milligram amounts than therapeutic-dose sessions. They are not designed to produce a dissociative experience.
Daily low-dose administration is distinct from the therapeutic-dose sublingual model described above. The dosing is lower, the frequency is higher, and the intended mechanism differs. Daily low-dose protocols aim for a pharmacological antidepressant-like effect rather than a session-based neuroplastic experience. To date, there is not peer-reviewed efficacy evidence supporting low-dose daily sublingual ketamine for depression at the level that exists for therapeutic-dose protocols studied in controlled or real-world outcomes research.
Not all sublingual ketamine is the same, and this distinction has practical consequences for outcomes. Readers evaluating at-home options should understand the difference in evidence base, protocol design, and intended therapeutic mechanism between these two approaches.
Subcutaneous Ketamine Therapy
Subcutaneous ketamine is injected just beneath the skin, typically into the abdomen. You use a small insulin-type needle for the injection. It can be self-administered at home as part of a supervised care program.
The subcutaneous route delivers approximately 90% of the dose to systemic circulation, exceeding sublingual absorption. You can expect to feel initial effects within about 5 minutes. Subcutaneous delivery provides more consistent absorption and session intensity compared to sublingual. Bypassing oral mucosa variability and first-pass metabolism creates this consistency.
Key differentiators versus sublingual ketamine include:
- Faster onset: Effects begin in about 5 minutes.
- Higher bioavailability: More medication reaches systemic circulation.
- Consistent intensity: Bypasses absorption variables in the mouth.
- Administration: Uses a small insulin needle rather than a tablet.
Mindbloom is the only at-home ketamine provider currently offering subcutaneous administration in addition to sublingual tablets. Offering both options gives clients and providers an additional way to personalize the care experience based on medical needs and preferences.
